AOD-9604

AOD-9604 is a synthetic peptide corresponding to the C-terminal region of human growth hormone, residues 177-191, with an added tyrosine at the N-terminus. It is supplied as a lyophilised powder. Identity is confirmed by mass spectrometry against the calculated mass and purity by reversed-phase HPLC with a stated gradient. Fragment peptides of this kind are frequently mislabelled in commerce, so mass-spectrometric identity confirmation on the batch certificate, rather than purity alone, is the value that matters. Analytical figures on this record come from supplier documentation.

The fragment was derived from work in the 1990s on the lipolytic region of the growth hormone molecule, which sought to separate effects on adipose tissue from the receptor-mediated growth and glucose effects of the intact hormone. The compound was advanced into human trials in the 2000s for an obesity indication and later pursued for an osteoarthritis indication. It did not obtain a marketing authorisation for either.

The trajectory of this compound is instructive for evaluating others in the same catalogue. Promising preclinical lipolysis data, a plausible mechanism and a clean early safety profile were sufficient to justify a clinical programme and insufficient to produce an effect in humans. Any compound presented here on the strength of preclinical data alone occupies the position this one occupied before its trial read out.

Published work examines lipolytic activity in adipose tissue preparations, effects on lipogenesis in cultured and isolated tissue systems, and the absence of growth hormone receptor-mediated effects such as IGF-1 elevation and impaired glucose tolerance. Rodent studies examined body composition endpoints. Later work examined cartilage and inflammatory endpoints in animal models.

The dissociation of the fragment from classical growth hormone receptor signalling is well supported: published human data show it does not produce the IGF-1 elevation or glucose effects associated with the intact hormone. In vitro and rodent lipolytic effects have been reported by more than one group. The human safety record from the completed clinical programme is comparatively substantial, with several hundred participants exposed in controlled settings.

The safety dataset is genuinely useful even though the efficacy result was negative. Several hundred participants were exposed under controlled conditions with systematic adverse-event collection, and the absence of the IGF-1 and glucose effects associated with intact growth hormone was measured directly in humans rather than inferred from the fragment's structure.

The most important fact about this compound is a negative one, and it is routinely omitted from promotional summaries: the randomised placebo-controlled human obesity trial did not demonstrate a significant weight-loss benefit over placebo at its primary endpoint. Development for that indication ended accordingly. Rodent findings therefore did not translate. The osteoarthritis work is preclinical and early-phase, with no completed pivotal trial. There are no independent replications of the positive rodent body-composition findings under blinded conditions with adequate power. Any presentation of this compound as an established fat-loss agent contradicts the strongest human evidence available.

Store the lyophilised solid as stated on this record, protected from light and moisture, equilibrating the sealed vial to ambient temperature before opening. Repeated freeze-thaw and prolonged solution storage are the handling variables most often implicated in degradation of peptides of this length. This section concerns laboratory handling of the material as supplied and contains no preparation or administration procedure.

Indexed citations with verified PMIDs are listed below. Analytical basis for the specification is described in testing methodology; documentation expectations appear in sourcing standards.